In the United States, federal government policy promotes the use of racially categorized data to identify and address health disparities between racial or ethnic groups. In clinical settings, race has sometimes been considered in the diagnosis and treatment of medical conditions. Doctors have noted that some medical conditions are more prevalent in certain racial or ethnic groups than in others, without being sure of the cause of those differences. Recent interest in race-based medicine, or race-targeted pharmacogenomics, has been fueled by the proliferation of human genetic data which followed the decoding of the human genome in the first decade of the twenty-first century. There is an active debate among biomedical researchers about the meaning and importance of race in their research. Proponents of the use of racial categories in biomedicine argue that continued use of racial categorizations in biomedical research and clinical practice makes possible the application of new genetic findings, and provides a clue to diagnosis.

Who promotes the use of racially categorized data in the United States?